UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGNPRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March, 2023.

Commission File Number: 001-40627

SOPHiA GENETICS SA

(Exact name of registrant as specified in itscharter)

Rue du Centre 172

CH-1025 Saint-Sulpice

Switzerland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F	☒	Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SOPHiA GENETICS SA
Date: March 14, 2023
	By:	/s/ Daan van Well
	Name:	Daan van Well
	Title:	Chief Legal Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release dated March 14, 2023

Exhibit 99.1

SOPHiA GENETICS and Agilent Partner on ComprehensiveSolution for Cancer Analysis

Collaboration provides a solution for a more in-depth analysis of cancer biomarkers

BOSTON and LAUSANNE, Switzerland, March 14, 2023– SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and the leader in data-driven medicine, is partnering with Agilent to offer a comprehensive solution for cancer analysis.

Through the partnership, the SOPHiA DDMTM Platform will be integrated with Agilent’s new Research Use Only SureSelect Cancer Comprehensive Genomic Profiling (CGP) Assay Kit. This will enable clinical researchers to accurately identify multiple biomarkers, lowering the risk of missing important information in cancer samples. The partnership brings together these two companies’ strengths in analytics and next generation sequencing (NGS) assay development to facilitate novel approaches to cancer research.

“Working with Agilent means combining best-in-class profiling practices with rich data and insights,” said Kevin Puylaert, Vice President, Business Development & Marketing, SOPHiA GENETICS. “Together, we can break traditional barriers that often limit new discoveries, democratizing access to data-driven medicine around the world.”

SOPHiA GENETICS is tailoring its analytics to work in harmony with Agilent’s target enrichment technology so that users have access to an advanced solution that allows multiple tumor markers to be detected. With the SOPHiA DDMTM Platform, users will have an integrated solution with reporting tools that go beyond simple readouts, aligned with the information and input from the latest guidelines and clinical trials reflecting relevant biomarkers.

“We chose to partner with SOPHiA GENETICS to leverage their analytical and reporting capabilities, which complements our SureSelect Cancer CGP panel, to drive toward providing clinical researchers with a complete set of tools that will make comprehensive tumor profiling possible in their own labs,” said Kevin Meldrum, Vice President and General Manager, Integrated Genomics Division, Agilent Technologies.

The combined efforts of Agilent and SOPHiA GENETICS will make it possible for labs of varying sizes to bring cancer analysis in-house without having to send out samples or output data to other vendors and labs. This keeps impactful bioinformatic information in the hands of the user for future reference or research.

TomaLab, one of the largest research and genetics laboratories in Italy, is participating in an early-access program that is currently underway.

“Our laboratory is excited by the Agilent and SOPHiA GENETICS partnership and the release of their integrated CGP solution,” said Vittorio Grazioli, CEO of TomaLab. “Combining high-quality reagents, automation options, and powerful analytics into one unique workflow will help us maximize insights from CGP data while improving our efficiency."

#

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. Where others see data, we see answers.

SOPHiA GENETICS products are for Research UseOnly and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products thatmay or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by agovernmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate productinformation for your country of residence.

SOPHiA GENETICS Forward-Looking Statements:

This press release contains statements that constituteforward-looking statements. All statements other than statements of historical facts contained in this press release, including statementsregarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectivesof management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefsand assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, andactual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, includingthose described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results willbe achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaimany obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in

ourexpectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicablelaw. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Media Contact:

Nick Puleo

npuleo@comsint.com